XML 21 R9.htm IDEA: XBRL DOCUMENT

Strategic Transaction and Integration Expenses (Notes)	3 Months Ended
Strategic Transaction and Integration Expenses (Notes)	Mar. 31, 2019
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Strategic Transaction and Integration Expenses We incurred and expensed $23.6 million and $19.8 million in transaction and integration expenses during the three months ended March 31, 2019 and 2018, respectively, primarily related to the integration of the Hospira Infusion Systems ("HIS") business acquired in 2017 from Pfizer.